Saxenda (liraglutide): uses, doses, cost and how to take it
The short answer
Saxenda is liraglutide, a once-daily GLP-1 injection from Novo Nordisk. It's approved for long-term weight reduction in adults with obesity, in adults with overweight and a weight-related condition, and in pediatric patients aged 12 and older with obesity who weigh more than 60 kg. The list price is $1,349.02, and Novo Nordisk has announced Saxenda will be discontinued.
Key takeaways
- Saxenda is a once-daily injection, and the label raises the dose each week up to 3 mg.
- Novo Nordisk has announced Saxenda will be discontinued, so talk with your prescriber early about what comes next.
- More than 3 days since your last dose? The label says restart at 0.6 mg. Check with your prescriber first.
- The label says adults who haven't lost at least 4% of baseline body weight by 16 weeks should stop.
- Medicare generally doesn't cover Saxenda, and it isn't one of the products in the Medicare GLP-1 Bridge.
On this page
- What is Saxenda approved for?
- Is Saxenda being discontinued?
- What doses does Saxenda come in?
- How do you take Saxenda?
- How well does Saxenda work?
- How much does Saxenda cost?
- Does insurance or Medicare cover Saxenda?
- What are the side effects of Saxenda?
- What if I miss a dose of Saxenda?
- How do I store Saxenda?
- Frequently asked questions
- Sources
Saxenda at a glance
| Active ingredient | liraglutide |
|---|---|
| Maker | Novo Nordisk |
| FDA-approved uses |
|
| Forms and strengths |
|
| Medicare GLP-1 Bridge | Not in the Bridge |
| Label | Revised: 6/2026 (DailyMed version 22) |
Saxenda dose schedule from the label
SaxendaRevised: 6/2026 (DailyMed version 22)
Put it on a calendar with the titration schedule builder. Only your prescriber decides when, and whether, your dose changes.
See every price
Every verified Saxenda price
| Where you buy | Form · dose | Price | Conditions | Source |
|---|---|---|---|---|
| List price | Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens) · All strengths | $1,349.02/fill | ConditionsNovo Nordisk states a single list price for Saxenda without naming the supply period; the price shown is per fill (one package). Novo Nordisk has announced Saxenda will be discontinued, with last shipments to wholesalers in late January 2027, and the Saxenda Savings Offer closed to new enrollees on June 30, 2023. | novocare.com |
Saxenda is Novo Nordisk’s brand of liraglutide for weight management. You inject it every day, while most medicines in this group are taken weekly or by mouth, and its maker has announced that it will be discontinued. If you take Saxenda, or you’ve been offered it, this guide covers what the FDA label (Revised: 6/2026 (DailyMed version 22)) says and what Novo Nordisk publishes about its price.
What is Saxenda approved for?
The label approves Saxenda to reduce excess body weight and keep it off long term in two groups:
- Adults, and pediatric patients aged 12 years and older with body weight greater than 60 kg, who have obesity.
- Adults with overweight who have at least one weight-related comorbid condition (a health problem linked to weight).
The label sets two limits. Saxenda isn’t recommended together with other liraglutide-containing products or with any other GLP-1 receptor agonist. And its safety and effectiveness haven’t been established in pediatric patients with type 2 diabetes.
Saxenda and liraglutide
Liraglutide is the drug. Saxenda is the brand name for liraglutide at the weight-management dosage. That’s why the label warns against combining Saxenda with any other liraglutide product: it would be a second dose of one drug.
Is Saxenda being discontinued?
Yes. Novo Nordisk has announced that Saxenda will be discontinued, with last shipments to wholesalers in late January 2027. That’s the manufacturer’s own statement.
What matters for you is timing. A prescription change takes an appointment, and possibly a new prior authorization (the plan’s approval before it pays). The label only describes how Saxenda itself is started. So the plan for what replaces it is one to make with your prescriber. Our guides to Wegovy, Zepbound and Foundayo describe the other medicines approved for weight reduction, and the switching planner shows what each label says. Our Saxenda vs Wegovy comparison sets those two medicines side by side.
What doses does Saxenda come in?
One pen delivers every dose. Each Saxenda pen contains 18 mg of liraglutide and can be dialed to 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg. The label’s schedule raises the dose once a week:
- Week 1: 0.6 mg daily.
- Week 2: 1.2 mg daily.
- Week 3: 1.8 mg daily.
- Week 4: 2.4 mg daily.
- Week 5 onward: 3 mg daily.
The label says this slow climb is there to reduce gastrointestinal (stomach and bowel) side effects. If you don’t tolerate an increased dose, it says to consider delaying the next step by approximately one additional week.
For adults, 3 mg daily is the recommended dosage, and the label is direct that lower dosages are for titration (stepping up) only. It says to stop Saxenda if an adult can’t tolerate 3 mg. For pediatric patients who don’t tolerate 3 mg, the maintenance dose (the dose you stay on) may be reduced to 2.4 mg daily.
The titration schedule tool puts these weekly steps on a calendar.
The 16-week checkpoint
The label builds in a review. Adults who haven’t lost at least 4% of their baseline (starting) body weight 16 weeks after starting Saxenda should stop it. It’s worth knowing before you start, so put week 16 on your calendar.
How do you take Saxenda?
You inject Saxenda once daily, at any time of day, with or without meals. It goes under the skin of your abdomen, thigh or upper arm. You can change the site or the time of day without adjusting the dose. The label says to rotate injection sites within the same region, to reduce the risk of cutaneous amyloidosis (lumps of protein that build up under the skin).
A few points about the pen itself:
- Needles aren’t included. The pen takes disposable needles up to 8 mm long, which you get separately.
- New needle each time. Remove and discard the needle after each injection, and store the pen without a needle attached.
- Never share a pen. Not even with a new needle, because of infection risk.
- Disposal. Used needles and pens go in an FDA-cleared sharps disposal container, not household trash.
A pen holds 18 mg, so it gives you six daily doses at 3 mg. Pens are sold in cartons of 3 or 5. The supply tracker can count down the doses left.
How well does Saxenda work?
The label reports its trials separately, and each figure belongs to its own trial.
- Adults without diabetes. In Study 1, a 56-week trial in adults with obesity or overweight, mean (average) body-weight change was -7.4% with Saxenda and -3% with placebo, a difference of -4.5%.
- Adults with type 2 diabetes. In Study 2, also 56 weeks, mean body-weight change was -5.4% with Saxenda and -1.7% with placebo, a difference of -3.7%.
- Keeping weight off. In Study 3, adults who had first lost at least 5% of body weight with a low-calorie diet changed by a further -4.9% on Saxenda and +0.3% on placebo over 56 weeks. The label cautions that this trial only included people who lost at least 5% during the diet run-in, so the results may not reflect the general population.
These are averages across trial groups, alongside diet and activity counseling. They don’t forecast your result, and they weren’t measured against other GLP-1 medicines.
How much does Saxenda cost?
The price Novo Nordisk publishes is the list price of $1,349.02, taken from its own page. Novo Nordisk states a single list price for Saxenda without naming the supply period, so we show it per package. List price is the price before any discount or rebate. Novo Nordisk says most people don’t pay it if their insurance covers weight-management medicines.
The Saxenda savings offer closed to new enrollees on June 30, 2023.
So for most people the real question is coverage. If your plan covers Saxenda, your price is your copay or coinsurance. If it doesn’t, ask your pharmacy for its cash price, and compare that with the manufacturers’ self-pay prices for the other weight-management medicines. The Saxenda cost page walks through this, and the cost calculator prices the other medicines on this site. The wider picture is in our GLP-1 cost guide.
Does insurance or Medicare cover Saxenda?
Commercial coverage of weight-management medicines varies widely. Some plans cover Saxenda with prior authorization. Some exclude the whole category. Call the number on your insurance card and ask about Saxenda by name. With a discontinuation announced, also ask which weight-management medicines the plan will cover next year. If you’re denied, the appeal letter generator drafts a request for your prescriber.
Medicare is more settled. The Part D statute excludes agents when used for weight loss, and CMS says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight loss indication. Saxenda’s approved uses are all weight reduction, so it has no other indication to qualify under. It’s also not among the products in the Medicare GLP-1 Bridge. If you have Medicare and want help paying for a weight-management medicine, the Bridge guide and the eligibility checker explain which medicines are included and who qualifies. The Medicare guide covers the rest.
What are the side effects of Saxenda?
Gastrointestinal effects lead the list. In the label’s adult trials, nausea was reported by 39.3 percent of patients on Saxenda and 13.8 percent on placebo. Diarrhea was reported by 20.9 percent (placebo 9.9 percent), constipation by 19.4 percent (placebo 8.5 percent) and vomiting by 15.7 percent (placebo 3.9 percent). Injection site reactions were reported by 13.9 percent (placebo 10.5 percent). Overall, approximately 68% of patients on Saxenda and 39% on placebo reported gastrointestinal disorders.
The label adds some context. Most gastrointestinal episodes were mild or moderate, and the percentage of patients reporting nausea declined as treatment continued. Even so, 6.2% of patients on Saxenda and 0.8% on placebo stopped treatment because of gastrointestinal reactions. Counting all adverse reactions, 9.8% of patients on Saxenda and 4.3% on placebo stopped early.
If you have type 2 diabetes, the label says lowering the dose of a sulfonylurea or insulin may reduce the risk of low blood sugar. That adjustment is your prescriber’s to make.
The boxed warning
Saxenda carries a boxed warning about thyroid C-cell tumors. In plain words: liraglutide caused thyroid C-cell tumors in rats and mice, and it’s unknown whether Saxenda causes them, including medullary thyroid carcinoma (MTC), in humans. Saxenda is contraindicated, meaning it must not be used, in people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and after a serious hypersensitivity (allergic) reaction to liraglutide or any ingredient.
Other warnings in the label include acute pancreatitis, acute gallbladder disease, low blood sugar, an increase in heart rate, acute kidney injury from dehydration, severe gastrointestinal reactions, serious allergic reactions, and aspiration (stomach contents entering the lungs) during general anesthesia or deep sedation. On gallbladder disease, 2.2% of adult patients on Saxenda reported gallstones, compared with 0.8% on placebo. Tell your healthcare providers you take Saxenda before any planned surgery or procedure.
If you become pregnant, the label says to stop Saxenda when the pregnancy is recognized. Unlike the semaglutide labels, it gives no number of months to stop before a planned pregnancy.
Contact a clinician promptly if you have severe abdominal pain that doesn’t go away, a racing heartbeat at rest that persists, or signs of an allergic reaction.
What if I miss a dose of Saxenda?
The rule has two parts, and the second one is easy to overlook.
One missed dose. Resume the once-daily regimen with your next scheduled dose. Don’t take an extra dose, and don’t increase the dose to make up for it.
More than 3 days without a dose. If more than 3 days have passed since your last Saxenda dose, the label says to restart at 0.6 mg daily and follow the weekly escalation schedule again. The reason given is to reduce the risk of gastrointestinal reactions on restarting. Check with your prescriber before you restart, since it changes how long your current pens will last.
The missed dose tool applies both parts to your dates.
How do I store Saxenda?
Before first use. Store the pen in a refrigerator at 36°F to 46°F (2°C to 8°C). Don’t keep it in the freezer or directly next to the refrigerator’s cooling element.
After first use. You can store the pen for 30 days at 59°F to 86°F (15°C to 30°C) or in a refrigerator. Throw it away after 30 days, even if some medicine remains.
Always. Don’t freeze Saxenda, and don’t use it if it has been frozen. Store the pen with no needle attached.
Frequently asked questions
How much does Saxenda cost?
The Saxenda price Novo Nordisk publishes is its list price of $1,349.02. Novo Nordisk states that figure without naming the supply period it covers. The Saxenda savings offer closed to new enrollees on June 30, 2023. What you pay depends on your insurance coverage.
What are the Saxenda doses?
The Saxenda pen delivers five doses: 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg. The label starts at 0.6 mg daily for one week and raises the dose each week, to 1.2 mg, 1.8 mg, 2.4 mg and then 3 mg from week 5 onward. For adults, 3 mg daily is the recommended dosage, and the lower doses are for titration (stepping up) only.
What should I do about a missed dose of Saxenda?
The label says to resume the once-daily regimen with your next scheduled dose. Don't take an extra dose or a larger dose to make up for the one you missed. If more than 3 days have passed since your last dose, the label says to restart at 0.6 mg daily and follow the escalation schedule again.
Is Saxenda the same medicine as liraglutide?
Liraglutide is the active drug in Saxenda, and Saxenda is the brand approved for long-term weight reduction at a dosage of 3 mg daily. The label says Saxenda shouldn't be used together with other liraglutide-containing products or with any other GLP-1 receptor agonist.
Is Saxenda being discontinued?
Yes, according to Novo Nordisk. The company has announced that Saxenda will be discontinued, with last shipments to wholesalers in late January 2027. If you take Saxenda, talk with your prescriber well ahead of that date about what comes next.
How many doses are in a Saxenda pen, and how long does it last?
Each pen contains 18 mg of liraglutide. That is 30 doses at 0.6 mg, 15 at 1.2 mg, 10 at 1.8 mg, 7 full doses at 2.4 mg or 6 at 3 mg. Pens come in cartons of 3 or 5. Once a pen is in use, the label says to throw it away after 30 days, even if medicine remains in it.
Does Medicare cover Saxenda?
Generally no. Saxenda's approved uses are for weight reduction, and CMS, the federal Medicare agency, says Medicare and Medicaid generally do not cover GLP-1 drugs for the weight loss indication. Saxenda also isn't one of the products available through the Medicare GLP-1 Bridge, which covers Foundayo, Wegovy and the Zepbound KwikPen.
When should Saxenda be stopped if it is not working?
The label sets a checkpoint for adults. If you haven't lost at least 4% of your baseline (starting) body weight 16 weeks after starting Saxenda, you should stop it. The label also says to stop Saxenda if an adult can't tolerate the 3 mg dose. You make both decisions with your prescriber.
Sources (27)
- 1.FDA label (DailyMed): Saxenda prescribing information, section 2.1
“Inject SAXENDA subcutaneously once daily at any time of day, without regard to the timing of meals.”
- 2.FDA label (DailyMed): Saxenda prescribing information, section 2.1
“Inject SAXENDA subcutaneously in the abdomen, thigh, or upper arm. No dosage adjustment is needed if changing the injection site and/or timing.”
- 3.FDA label (DailyMed): Saxenda prescribing information, section 2.1
“Rotate injection sites within the same region in order to reduce the risk of cutaneous amyloidosis”
- 4.FDA label (DailyMed): Saxenda prescribing information, section 2.1
“If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
- 5.FDA label (DailyMed): Saxenda prescribing information, section 16
“Prior to first use, SAXENDA should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Do not store in the freezer or directly adjacent to the refrigerator cooling element.”
- 6.FDA label (DailyMed): Saxenda prescribing information, section 16
“After initial use of the SAXENDA pen, the pen can be stored for 30 days at controlled room temperature 59°F to 86°F (15°C to 30°C) or in a refrigerator 36°F to 46°F (2°C to 8°C). Keep the pen cap on when not in use. Protect SAXENDA from excessive heat and sunlight.”
- 7.FDA label (DailyMed): Saxenda prescribing information, section 16
“Do not freeze SAXENDA and do not use SAXENDA if it has been frozen.”
- 8.FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
“It contains 18 mg of liraglutide, and you can select doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3 mg.”
- 9.FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
“Your pen is made to be used with disposable needles up to a length of 8 mm. Pen needles are not included with your Saxenda pen.”
- 10.FDA label (DailyMed): Saxenda prescribing information, section 16
“Always remove and safely discard the needle after each injection and store the SAXENDA pen without an injection needle attached. This will reduce the potential for contamination, infection, and leakage while also ensuring dosing accuracy.”
- 11.FDA label (DailyMed): Saxenda prescribing information, section 17
“Inform patients that they should never share a SAXENDA pen with another person, even if the needle is changed. Sharing of the pen between patients may pose a risk of transmission of infection.”
- 12.FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
“The Saxenda pen you are using should be thrown away after 30 days, even if it still has Saxenda left in it.”
- 13.FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
“Do not throw away in the household trash. Put the needle and any empty Saxenda pen or any pen used for 30 days still containing Saxenda in an FDA-cleared sharps disposal container right away after use.”
- 14.FDA label (DailyMed): Saxenda prescribing information, section 8.1
“Additionally, weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus, and discontinue SAXENDA”
- 15.FDA label (DailyMed): Saxenda prescribing information, section 5.4
“The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin.”
- 16.FDA label (DailyMed): Saxenda prescribing information, section 14.1, Table 4
“After 56 weeks, treatment with SAXENDA resulted in a statistically significant reduction in weight compared with placebo.”
- 17.FDA label (DailyMed): Saxenda prescribing information, section 14.1, Table 4
“Study 2 was a 56-week trial that enrolled 635 patients with type 2 diabetes and with either overweight or obesity (as defined above).”
- 18.FDA label (DailyMed): Saxenda prescribing information, section 14.1, Table 4
“In Study 3, statistically significantly more patients randomized to SAXENDA than placebo had not gained more than 0.5% of body weight from randomization to Week 56.”
- 19.FDA label (DailyMed): Saxenda prescribing information, section 14.1
“Because losing at least 5% of fasting body weight through lifestyle intervention during the 4- to 12-week run-in was a condition for their continued participation in the randomized treatment period, the results may not reflect those expected in the general population.”
- 20.FDA label (DailyMed): Saxenda prescribing information, section 2.2
“Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.”
- 21.FDA label (DailyMed): Saxenda prescribing information, section 1
“SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
- 22.FDA label (DailyMed): Saxenda prescribing information, section 4
“Patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)”
- 23.FDA label (DailyMed): Saxenda prescribing information, section 4
“Patients with a serious hypersensitivity reaction to liraglutide or to any of the excipients in SAXENDA. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with SAXENDA”
- 24.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
- 25.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 26.
- 27.
